Suzy Jones is ready to make a deal.
DNA Ink LLC already has two active clients — an oncology diagnostic company and a small molecule developer — and a couple more in the queue, Jones said. It charges on contingency, taking a cut as a percentage upfront or on the back end of a completed deal.
The 20-year Genentech Inc. veteran — one of a handful of top executives to leave the South San Francisco-based biotech powerhouse since its acquisition by Roche Group — is launching her own business development firm aimed at helping small biotechs negotiate deals with Big Pharma and Big Biotech.
No comments:
Post a Comment